乳腺癌患者血清可溶性晚期糖基化终末产物受体水平及其临床意义  

Level and clinical significance of serum soluble receptor for advanced glycation end-products in patients with breast cancer

作　　者：程学远[1] 覃庆洪[2] 黄忠[1] CHENG Xue-yuan;QIN Qing-hong;HUANG Zhong(Department of General Surgery,Beihai People's Hospital,Beihai 536000,China;Department of Breast Surgery,Guangxi Medical University Affiliated Tumor Hospital,Nanning 530021,China)

机构地区：[1]广西北海市人民医院普通外科,北海市536000 [2]广西医科大学附属肿瘤医院乳腺外科,南宁市530021

出　　处：《广西医学》2020年第1期10-13,共4页Guangxi Medical Journal

基　　金：广西自然科学基金(2017GXNSFAA198088,2015GXNSFAA139204);广西北海市本级科学研究与技术开发项目(201602028)

摘　　要：目的探讨乳腺癌患者血清可溶性晚期糖基化终末产物受体(sRAGE)水平及其临床意义。方法选取80例乳腺癌患者和80例健康体检者为研究对象,应用酶联免疫吸附法测定两组血清sRAGE水平。分析乳腺癌患者血清sRAGE水平与临床病理特征的关系,并采用受试者工作特征曲线评价血清sRAGE对乳腺癌的诊断效能。结果乳腺癌患者血清sRAGE水平低于健康体检者(P<0.05)。TNM分期Ⅰ~Ⅱ期、无淋巴转移的乳腺癌患者血清sRAGE水平分别高于TNM分期Ⅲ期、淋巴转移的患者(P<0.05)。血清sRAGE诊断乳腺癌的受试者工作特征曲线下面积为0.849(P<0.05),敏感性为91.85%,特异性为77.41%。结论sRAGE在乳腺癌患者血清中呈低表达,其或与乳腺癌的发生、发展有关,并有望成为临床诊断乳腺癌的生物学标志物。Objective To investigate the level and clinical significance of serum soluble receptor for advanced glycation end-products(sRAGE)in patients with breast cancer.Methods Eighty breast cancer patients and 80 healthy individuals undergoing medical examination were selected as subjects,serum sRAGE level was measured in the two groups by enzyme-linked immunosorbent assay.The relationship between serum sRAGE level and clinicopathological characteristics was analyzed in patients with breast cancer,and receiver operating characteristic curve was used to evaluate the diagnostic efficiency of serum sRAGE for breast cancer.Results Patients with breast cancer had lower serum sRAGE level than healthy check-up individuals(P<0.05).Serum sRAGE levels in breast cancer patients with TNM stageⅠtoⅡ,and without lymphatic metastasis were lower than those with TNM stageⅢ,and with lymphatic metastasis,respectively(P<0.05).The area under the receiver operating characteristic curve of serum sRAGE for diagnosing breast cancer was 0.849(P<0.05),with a sensitivity of 91.85%and a specificity of 77.41%.Conclusions sRAGE is lowly expressed in the serum of breast cancer patients,which might be associated with the development and progression of breast cancer,and acts as a promising biomarker for clinical diagnosis of breast cancer.

关 键 词：乳腺癌 可溶性晚期糖基化终末产物受体 诊断效能 临床特征 病理特征 

分 类 号：R737.9[医药卫生—肿瘤]